B-161 Clinical Application of Magnetic Particle Chemiluminescence Method for Detecting HBV PreS1 in Chronic HBV Infection

Abstract

Background To detect the role of PreS1 in different stages of chronic HBV infection and to explore its potential as a predictor of HBsAg clearance. Methods Quantitative detection of HBV PreS1 was performed on serum samples from 594 patients with chronic HBV infection, chronic hepatitis B (CHB), liver cirrhosis (LC), and hepatocellular carcinoma (HCC). The cohort of HBeAg-negative patients receiving pegylated interferon (Peg-IFN) treatment was divided into the HBsAg seroclearance group and the HBsAg non-seroclearance group based on whether HBsAg was cleared at 48 weeks. The level of PreS1 was detected using magnetic particle chemiluminescence method. Results The level of PreS1 varied in different natural history periods and was correlated with HBV serum markers. The level of PreS1 had a high diagnostic value in the diagnosis of HBV infection stages. The baseline levels of PreS1 and HBsAg in the HBsAg seroclearance group were significantly lower than those in the HBsAg non-seroclearance group. The combination of baseline PreS1 and HBsAg levels had a better predictive value for HBsAg clearance. In the HBsAg seroclearance group, PreS1 disappeared before HBsAg; in the HBsAg non-seroclearance group, PreS1 partially disappeared. The rate of decline of PreS1 and HBsAg in the HBsAg seroclearance group was faster than that in the HBsAg non-seroclearance group. The level of PreS1 in CHB patients was significantly higher than that in LC and HCC patients. Conclusion The baseline level of PreS1 is not only an important biomarker for differentiating chronic HBV infection from CHB, but also can predict HBsAg clearance in HBeAg-negative patients after Peg-IFN treatment.